Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Magnificence of Extraordinariness: Presenting Valuable Adornments and Gemstones - 2The most effective method to Shake Hands During a Pandemic: Wellbeing Tips and Behavior
- 3I tried a macho, creatine-loaded cereal “for men.” Did I mention I'm a woman?
- 410 Demonstrated Tips to Boost Your New Android Cell phone: A Thorough Aide
- 5Why More Couples Are Choosing Africa For Their Honeymoon
- The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- April's full moon decides the date of Easter — here's how it works
- Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- Israel, Gulf states report fresh missile and drone attacks
- Saucony's $125 'Comfy, Stylish' Sneakers Are Now $55
- European Travel Objections for 2024
- Home Wellness Basics: Building Your Home Exercise center
- Factbox-China's crewed lunar programme eyes astronaut landing by 2030
- Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
